|
|
||||||||
Institute of Immunology, University of Heidelberg, Heidelberg, Germany
The 60-kDa lymphocyte function-associated Ag-3 (LFA-3/CD58), a
highly glycosylated adhesion molecule that serves as ligand for the T
cell-restricted glycoprotein CD2, is encoded by a gene at the human
chromosome locus 1p13. We have elucidated the exon-intron organization
of the entire human CD58 gene, including
2.5 kilobases
(kb) of 5'-flanking DNA. Four overlapping genomic clones, spanning
65 kb, contained the entire
1-kb coding sequence of CD58 and
consisted of six separate exons, which varied from 72 to 294 bp in
size. At least two different CD58 mRNA precursors can be generated from
the human gene as a result of alternative choice of one of the two
acceptor splice sites located within exon 5. DNA sequence analysis of
about 2.5 kb of 5'-flanking sequence of the CD58 gene
indicated the absence of a CAAT box. However, potential binding sites
for the transcriptional activators AP-2, GATA, PU.1, and Sp-1 are
present. Two consensus TATAA elements, located
2.4 kb upstream of
the transcriptional start site, have been identified. The 2.5-kb CD58
promoter sequence displayed functional activity in transient
transfection assays in the hepatocellular carcinoma cell line HepG2.
Comparing the response of CD58 promoter-driven luciferase plasmids to
several cytokines and other agents suggests that the CD58 promoter is
regulated by up-regulatory, enhancer-like and down-regulatory,
silencer-like elements. Further analysis of this region should allow
researchers to gain insight into the molecular mechanisms by which this
gene is regulated, e.g., during inflammatory responses.
This article has been cited by other articles:
![]() |
J. S. Manavalan, S. Kim-Schulze, L. Scotto, A. J. Naiyer, G. Vlad, P. C. Colombo, C. Marboe, D. Mancini, R. Cortesini, and N. Suciu-Foca Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity Int. Immunol., August 1, 2004; 16(8): 1055 - 1068. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |